A biotechnology firm has developed a novel non-invasive stool DNA assay for colorectal cancer. To validate the assay's performance, a study is conducted in a high-risk gastrointestinal clinic among patients presenting with hematochezia. In this validation cohort, the prevalence of colorectal cancer is . The assay demonstrates a sensitivity of and a specificity of .
Following regulatory approval, a large health maintenance organization (HMO) decides to implement this stool DNA assay as a primary screening tool for all asymptomatic, average-risk members aged 50 to 75. Epidemiological data indicates that the point prevalence of colorectal cancer in this average-risk HMO population is .
Assuming the test's intrinsic performance characteristics remain constant across populations, what is the approximate probability that an average-risk HMO member with a positive stool DNA assay result actually has colorectal cancer?
- A
- B
- Answer
- D
- E